ELISA Kit for Phospholipase A2 Group VII (PLA2G7)
LpPLA2; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- Product No.SEA867Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.625-40ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.232ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 630
For more details, please contact local distributors! US$ 2835
For more details, please contact local distributors! US$ 5355
For more details, please contact local distributors! US$ 44100
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Phospholipase A2 Group VII (PLA2G7).
No significant cross-reactivity or interference between Phospholipase A2 Group VII (PLA2G7) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Phospholipase A2 Group VII (PLA2G7) and the recovery rates were calculated by comparing the measured value to the expected amount of Phospholipase A2 Group VII (PLA2G7) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Phospholipase A2 Group VII (PLA2G7) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Phospholipase A2 Group VII (PLA2G7) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Phospholipase A2 Group VII (PLA2G7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
|Science & Sports||The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women ScienceDirect: S0765159710000262|
|Metabolic Syndrome and Related Disorders||Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease Wiley: source|
|34||Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study PubMed: 22240497|
|PLoS ONE||Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo PubMed: PMC3759413|
|China Pharmacy||Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats Source|
|Atherosclerosis||Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Pubmed: 23958269|
|Journal of Diabetes Research||Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Hindawi: 278063|
|Health||The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia Scirp:Source|
|Biology Bulletin||In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood Springer:Source|
|Gynecol Endocrinol.||Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. Pubmed:24397392|
|Journal of Diabetes Research||Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Pubmed:24818163|
|Metabolism.||Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Pubmed:25034387|
|J Am Heart Assoc||Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients PubMed: 26374297|
|Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie||V Ebscohost|
|Endocrinol Metab (Seoul).||Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome pmc:PMC4803547|
|Clin Pharmacol Ther.||Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery Pubmed:25773594|
|Lipids in Health and Disease||Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … articles:10.1186|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|APA867Hu01||Active Phospholipase A2 Group VII (PLA2G7)||Cell culture; Activity Assays.|
|RPA867Hu01||Recombinant Phospholipase A2 Group VII (PLA2G7)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA867Hu01||Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IP.|
|LAA867Hu81||FITC-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IF.|
|LAA867Hu71||Biotin-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC.|
|MAA867Hu22||Monoclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IP.|
|SEA867Hu||ELISA Kit for Phospholipase A2 Group VII (PLA2G7)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SCA867Hu||CLIA Kit for Phospholipase A2 Group VII (PLA2G7)||Chemiluminescent immunoassay for Antigen Detection.|